Proxalutamide (GT0918) Improves Lung Injury in Hospitalized COVID-19 Patients -an Analysis of the Radiological Findings of the Proxa-Rescue AndroCoV Trial
Medeiros et al.,
Proxalutamide (GT0918) Improves Lung Injury in Hospitalized COVID-19 Patients -an Analysis of the Radiological..,
ResearchGate (Preprint), NCT04728802
Analysis of radiological findings from the Proxa-Rescue AndroCoV trial showing that proxalutamide significantly improves lung opacities compared to placebo.
NCT04728802 (history).
Abstract: See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/352881715
Proxalutamide (GT0918) Improves Lung Injury in Hospitalized COVID-19
Patients -an Analysis of the Radiological Findings of the Proxa-Rescue
AndroCoV Trial
Preprint · July 2021
DOI: 10.1101/2021.07.01.21259656
CITATIONS
READS
2
654
23 authors, including:
Claudia Elizabeth Thompson
Ricardo Ariel Zimerman
Universidade Federal de Ciências da Saúde de Porto Alegre
Hospital da Brigada Militar de Porto Alegre
171 PUBLICATIONS 677 CITATIONS
31 PUBLICATIONS 173 CITATIONS
SEE PROFILE
SEE PROFILE
Carlos Gustavo Wambier
Cadegiani Flávio
Alpert Medical School - Brown University
Applied Biology
152 PUBLICATIONS 1,268 CITATIONS
119 PUBLICATIONS 749 CITATIONS
SEE PROFILE
Some of the authors of this publication are also working on these related projects:
Adrenal Fatigue as a myth View project
The Sion Publishing House View project
All content following this page was uploaded by Cadegiani Flávio on 01 July 2021.
The user has requested enhancement of the
SEE PROFILE
Proxalutamide (GT0918) Improves Lung Injury in Hospitalized COVID-19
Patients – an Analysis of the Radiological Findings of the Proxa-Rescue AndroCoV
Trial
Flávio Adsuara Cadegiani, MD, PhD1,2*, Daniel do Nascimento Fonseca, MD3, Michael
do Nascimento Correia, MD4, Renan Nascimento Barros, MD5, Dirce Costa Onety,
MD3, Karla Cristina Petruccelli Israel, MD6,7, Emilyn Oliveira Guerreiro3, José Erique
Miranda Medeiros3, Raquel Neves Nicolau3, Luiza Fernanda Mendonça Nicolau3,
Rafael Xavier Cunha3, Maria Fernanda Rodrigues Barroco3, Patrícia Souza da Silva3,
Raysa Wanzeller de Souza Paulain, MD5, Claudia Elizabeth Thompson, PhD8, Ricardo
Ariel Zimerman, MD9, Carlos Gustavo Wambier, MD, PhD10, Andy Goren, MD2
1Corpometria
Institute, Brasilia, Brazil.
Applied
Biology,
Inc. Irvine, CA, USA.
2
3Samel & Oscar Nicolau Hospitals, Manaus, Brazil
4Hospital Regional José Mendes, Itacoatiara, Amazonas, Brazil
5Hospital Municipal Jofre Cohen, Parintins, Amazonas, Brazil
6Centro de Doenças Renais do Amazonas, Manaus, Brazil
7Programa de Pós-Graduação em Medicina Tropical – FMT/UEA, Manaus, Brazil
8Department of Pharmacosciences, Universidade Federal de Ciências da Saúde de Porto
Alegre
9Hospital da Brigada Militar, Porto Alegre, Brazil
10Department of Dermatology, Alpert Medical School of Brown University, Providence,
RI, USA.
*Corresponding author:
Flavio Adsuara Cadegiani, MD, PhD
Applied Biology, Inc.
17780 Fitch
Irvine, CA 92614
f.cadegiani@gmail.com
Abstract Word Count: 407
Text-Only Word Count: 2914
Total Number of References: 26
Tables (#): 2
Figures (#): 2
Abstract
Introduction: Antiandrogen are good candidates against the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) due to the inhibition of its
entry into host cells by the suppression of TMPRSS2, an enzyme that primes the SARSCoV-2 spike (S) protein and is key for its cell entry. Proxalutamide is a secondgeneration nonsteroidal anti-androgen (NSAA) with strong activities on androgen
receptor (AR) antagonism, suppression of AR nuclear expression, and downregulation
of the membrane-attached angiotensin converting enzyme-2 (ACE2). The efficacy of
proxalutamide was previously demonstrated for early COVID-19 patients, and has now
demonstrated efficacy to reduce deaths in hospitalized COVID-19 patient in a doubleblind, placebo-controlled randomized clinical..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit